Wednesday, July 11, 2012 6:09:42 PM
In 1968, IMS began business with the launch of unit dose emergency drugs. Over the years, the company continued its growth through the licensing of their products to major manufacturers of drugs and health care products.
In 1998, Amphastar acquired IMS from Medeva, PLC, a London based pharmaceutical company. Under Amphastar's management, IMS experienced tremendous growth in research and development.
IMS is a federally registered manufacturer of sterile injectable pharmaceuticals. These sterile injectables are used with a wide variety of IMS delivery systems, including prefilled syringes and vials.
IMS maintains an excellent regulatory/cGMP compliance record and has a wealth of experience in dealing with Federal, and local regulatory agencies. Our facilities are registered and inspected regularly by the United States Food and Drug Administration (FDA), the United States Drug Enforcement Agency (DEA), and the California State Food and Drug Board.
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM